Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

INTRODUCTION: Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC). Data comparing their effects on patient-reported outcomes (PROs) from routine clinical practice are limited. METHODS: AQUARiUS (NCT02813...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiery-Vuillemin, Antoine, Hvid Poulsen, Mads, Lagneau, Edouard, Ploussard, Guillaume, Birtle, Alison, Dourthe, Louis-Marie, Beal-Ardisson, Dominique, Pintus, Elias, Trepiakas, Redas, Antoni, Laurent, Lukac, Martin, Van Sanden, Suzy, Pissart, Geneviève, Reid, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088345/
https://www.ncbi.nlm.nih.gov/pubmed/30116592
http://dx.doi.org/10.1136/esmoopen-2018-000397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088345/
https://www.ncbi.nlm.nih.gov/pubmed/30116592
http://dx.doi.org/10.1136/esmoopen-2018-000397

Ejemplares similares